The rapid expansion of GLP-1 therapies is creating a more complex healthcare environment in which medicines, compounded formulations and nutritional support are increasingly discussed together. Talking Medicines is drawing attention to the importance of distinguishing between these categories, particularly as patient and healthcare professional conversations move beyond individual treatments towards broader questions about metabolic health, access, lifestyle and long-term care.
GLP-1 receptor agonists are prescription medicines designed to imitate the effects of glucagon-like peptide-1, a hormone released naturally after eating. By activating GLP-1 receptors, these treatments can help regulate blood glucose, slow gastric emptying and increase feelings of fullness. They are used in approved clinical settings that include type 2 diabetes and, for certain products, weight management.
Medicines including semaglutide and liraglutide, alongside dual agonists such as tirzepatide, have become a significant area of clinical research and treatment. Research is also examining their potential relevance across cardiovascular disease, chronic kidney disease, obstructive sleep apnoea and other conditions associated with obesity.
The distinction between approved and compounded products is central to understanding the development of this market. FDA-approved GLP-1 therapies are manufactured under strict Good Manufacturing Practice conditions, with validated controls covering peptide synthesis, potency, sterility, stability and final packaging. They are also supported by clinical trial programmes assessing safety, pharmacokinetics, pharmacodynamics and longer-term outcomes.
This framework provides consistency across manufacturing batches and establishes a defined regulatory pathway. It also creates a clear separation between commercially manufactured therapies and compounded versions, which do not undergo the same premarket review or manufacturing validation.
Compounded GLP-1 medications became more prominent during periods when shortages restricted access to some approved products. Under specific legal conditions in the United States, certain compounding activity has been permitted during shortages. However, the FDA has stated that shortages affecting semaglutide and tirzepatide injection products have been resolved, changing the regulatory position for businesses producing products that are effectively copies of approved medicines.
Compounding may still be considered in limited, patient-specific circumstances where it is legally permitted and clinically appropriate. Examples could include the need for a different dosage strength or the avoidance of particular inactive ingredients. Even in these cases, compounded GLP-1 products remain distinct from FDA-approved treatments.
The changing shortage position introduces an important timing and compliance consideration across the GLP-1 ecosystem. As access to approved products improves, manufacturing standards, regulatory status and product classification are likely to play a greater role in how patients and healthcare professionals assess available options.
Nutritional compounds add another layer to the conversation. Creatine, for example, is a naturally occurring chemical compound involved in energy production during high-intensity activity. It does not regulate appetite or blood glucose in the same way as a GLP-1 medicine, and it is not a compounded drug. However, it may be included in customised nutritional formulations alongside electrolytes, amino acids or carbohydrates.
Interest in creatine has also developed around the question of maintaining lean body mass during weight loss. GLP-1 therapy can be associated with reductions in both fat mass and lean body mass, leading to wider discussion of resistance exercise, adequate protein intake and nutritional supplementation. Evidence specifically examining creatine use among people receiving GLP-1 therapy remains limited, and further research is continuing.
Other nutritional considerations may include protein supplementation, omega-3 fatty acids, dietary fibre and electrolytes. These products are not substitutes for prescription medicines and do not alter the pharmacological mechanism of GLP-1 therapies. Instead, they may form part of a broader approach to nutrition, hydration, muscle maintenance and functional health under appropriate professional guidance.
The separation between approved medicines, compounded formulations and nutritional products is therefore more than a technical distinction. Each category operates within a different regulatory, manufacturing and clinical framework. Confusion between them can affect treatment expectations, perceptions of safety and the way healthcare information is interpreted.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
